Adamed Pharma, together with the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences in Warsaw and the University of Gdańsk is beginning research on the development and clinical development of modern vaccines based on mRNA / VLP technology, directed against emerging zoonoses.  

The consortium received a grant of PLN 58.5 million for its project from the Medical Research Agency.

The main goal of the submitted project is to develop an innovative vaccine based on mRNA / VLP technology against zoonotic viral pathogens. The COVID-19 pandemic has shown that emerging zoonotic viruses can spread through societies around the world at an unprecedented rate and can mutate into new variants very quickly.

The assumption of the project is to develop a vaccine that will have significant advantages over the currently available preparations. In the case of the SARS-CoV-2 vaccine, it will have more favorable storage conditions than the current mRNA vaccines. The new vaccine also has the chance to show higher efficacy against new virus variants that are resistant to the current preparations.